Clinical standard · medication safety
Cumulative organ burden in polypharmacy
Clinical problem
A pairwise interaction check looks at two drugs. For n drugs there are n(n−1)/2 pairs, and three-way or more complex effects are not part of that count.
Drugs acting on the same organ can add up. Two or three risks that each look minor can together form a clinically relevant burden.
Example: an older patient on a diuretic and an ACE inhibitor is given an NSAID for pain. No single pair may be contraindicated. Together, the three raise the risk of acute kidney injury.
Safety planes
| Plane | Mechanism | Primary monitoring |
|---|---|---|
| Renal burden | Reduced renal perfusion (NSAID, ACE inhibitor or ARB, diuretic); direct tubular toxicity (e.g. aminoglycosides, vancomycin) | Serum creatinine, eGFR, potassium |
| Cardiac · QTc | Additive IKr block; diuretic-induced hypokalaemia and hypomagnesaemia | QTc on ECG, potassium, magnesium |
| Hepatic burden | Additive hepatotoxic drugs; plasma levels raised by CYP inhibition | ALT, AST, ALP, total bilirubin |
| Anticholinergic · CNS | Additive muscarinic receptor block; added sedative effects | No laboratory marker; confusion, falls, urinary retention and constipation are monitored clinically |
The drugs in the table are class examples, not a complete list.
The triple whammy
Glomerular filtration depends on the balance between the arterioles on either side of the glomerulus. Prostaglandins widen the afferent (incoming) arteriole. Angiotensin II narrows the efferent (outgoing) arteriole.
An NSAID suppresses prostaglandin synthesis, so the afferent arteriole narrows. An ACE inhibitor or ARB relaxes the efferent arteriole. A diuretic lowers circulating volume. Together they lower glomerular pressure from both sides, and the kidney cannot compensate.
In the nested case-control study by Lapi and colleagues, triple therapy was associated with a higher risk of acute kidney injury. The risk was highest in the first 30 days of use.
What PharmaDeux does with this burden
PharmaDeux checks an order across 18 safety planes. The planes under organ toxicity and cumulative burden assess drugs together, not one at a time.
Each finding is shown with the rule, value and threshold that triggered it. Thresholds are configured to the institution's clinical policy.
The design goal is context-aware alerting: showing findings that load the same organ together and reducing alert fatigue. The clinical effect of this goal has not yet been measured in an institution.
The physician makes the final decision. When the physician overrides an alert with a reason, the decision is written to the audit trail.
Limits
- Organ reserve changes over time. A rule reads the latest measured laboratory value, so dehydration or an acute change not yet reflected in the laboratory is invisible to it.
- Idiosyncratic reactions (unpredictable reactions not related to dose) cannot be predicted from cumulative burden.
- The product information (SmPC) and the physician's clinical judgement take precedence.
Clinical review: this page has not been reviewed by a physician yet.
References
- 1Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525.
This page is for information only and is not for clinical decisions. Decisions rest on the product information (SmPC/PIL), current guidelines and the physician's judgement. Last updated: 13 October 2026